Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

Summary

This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will be enrolled and treated in the study.

Timeline

Start

2012-01

Primary completion

2014-10

Completion

2014-10

Outcome

Outcome not reported

Stopped (Enrollment): “low enrollment r/t requirement of prior treatment with denileukin diftitox”

Drugs

Indications